Literature DB >> 12507300

Molecular biology of glioma tumorigenesis.

M L Ware1, M S Berger, D K Binder.   

Abstract

Gliomas are the most common intracranial malignant tumors in humans, and high-grade gliomas in particular pose a unique challenge due to their propensity for proliferation and tissue invasion. Our understanding of glioma oncogenesis, proliferation, and invasion has been greatly advanced in the past 10 years as researchers have gained a better understanding of the molecular biology of these tumors. This article highlights glioma histopathology, as well as cytogenetic and molecular alterations associated with the pathogenesis of human gliomas. It is hoped that better understanding of the molecular pathogenesis of gliomas will improve tumor classification as well as lead to novel targets for therapy and prognostic markers.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12507300     DOI: 10.14670/HH-18.207

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN: 0213-3911            Impact factor:   2.303


  13 in total

1.  Vitamin D receptor expression is associated with improved overall survival in human glioblastoma multiforme.

Authors:  Débora G Salomón; María E Fermento; Norberto A Gandini; María J Ferronato; Julián Arévalo; Jorge Blasco; Nancy C Andrés; Jean C Zenklusen; Alejandro C Curino; María M Facchinetti
Journal:  J Neurooncol       Date:  2014-03-01       Impact factor: 4.130

2.  Heme oxygenase-1 expression in human gliomas and its correlation with poor prognosis in patients with astrocytoma.

Authors:  Norberto A Gandini; María E Fermento; Débora G Salomón; Diego J Obiol; Nancy C Andrés; Jean C Zenklusen; Julián Arevalo; Jorge Blasco; Alejandro López Romero; María M Facchinetti; Alejandro C Curino
Journal:  Tumour Biol       Date:  2014-03

Review 3.  Gene therapy for high-grade glioma: current approaches and future directions.

Authors:  Atsushi Natsume; Jun Yoshida
Journal:  Cell Adh Migr       Date:  2008-07-13       Impact factor: 3.405

4.  Molecular-genetic characterisation of gliomas that recur as same grade or higher grade tumours.

Authors:  T J M Hulsebos; D Troost; S Leenstra
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-05       Impact factor: 10.154

5.  Ghrelin and the growth hormone secretagogue receptor constitute a novel autocrine pathway in astrocytoma motility.

Authors:  Vishwa Deep Dixit; Ashani T Weeraratna; Hyunwon Yang; Dorothy Bertak; Anthony Cooper-Jenkins; Gregory J Riggins; Charles G Eberhart; Dennis D Taub
Journal:  J Biol Chem       Date:  2006-03-09       Impact factor: 5.157

6.  Prognostic value of Mdm2, p53 and p16 in patients with astrocytomas.

Authors:  Stella M Ranuncolo; Mirta Varela; Ana Morandi; José Lastiri; Silvia Christiansen; Elisa Bal de Kier Joffé; María G Pallotta; Lydia Puricelli
Journal:  J Neurooncol       Date:  2004-06       Impact factor: 4.130

7.  Hugl-1 inhibits glioma cell growth in intracranial model.

Authors:  Xuejiao Liu; Dong Lu; Peng Ma; Huaqiang Liu; Yuewen Cao; Ben Sang; Xianlong Zhu; Qiong Shi; Jinxia Hu; Rutong Yu; Xiuping Zhou
Journal:  J Neurooncol       Date:  2015-09-04       Impact factor: 4.130

8.  Alteration of serum and tumoral neural cell adhesion molecule (NCAM) isoforms in patients with brain tumors.

Authors:  Laura Todaro; Silvia Christiansen; Mirta Varela; Paola Campodónico; M Guadalupe Pallotta; José Lastiri; Eugenia Sacerdote de Lustig; Elisa Bal de Kier Joffé; Lydia Puricelli
Journal:  J Neurooncol       Date:  2007-01-10       Impact factor: 4.506

9.  Up-regulation of miR-663a inhibits the cancer stem cell-like properties of glioma via repressing the KDM2A-mediated TGF-β/SMAD signaling pathway.

Authors:  Lei Wang; Bojuan Lang; Youdong Zhou; Jinyang Ma; Keqi Hu
Journal:  Cell Cycle       Date:  2021-08-23       Impact factor: 5.173

10.  Dual effect of serum amyloid A on the invasiveness of glioma cells.

Authors:  Franciele Hinterholz Knebel; Renata Chaves Albuquerque; Renato Ramos Massaro; Silvya Stuchi Maria-Engler; Ana Campa
Journal:  Mediators Inflamm       Date:  2013-02-25       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.